Cargando…

New Nanoparticle Formulation for Cyclosporin A: In Vitro Assessment

Cyclosporin A (CsA) is a molecule with well-known immunosuppressive properties. As it also acts on the opening of mitochondrial permeability transition pore (mPTP), CsA has been evaluated for ischemic heart diseases (IHD). However, its distribution throughout the body and its physicochemical charact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gendron, Amandine, Lan Linh Tran, Natalie, Laloy, Julie, Brusini, Romain, Rachet, Aurélie, Gobeaux, Frédéric, Nicolas, Valérie, Chaminade, Pierre, Abreu, Sonia, Desmaële, Didier, Varna, Mariana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828155/ https://www.ncbi.nlm.nih.gov/pubmed/33445646 http://dx.doi.org/10.3390/pharmaceutics13010091

Ejemplares similares

Development and Characterization of Innovative Multidrug Nanoformulation for Cardiac Therapy
por: Gendron, Amandine, et al.
Publicado: (2023)

Assessment of Squalene-Adenosine Nanoparticles in Two Rodent Models of Cardiac Ischemia-Reperfusion
por: Brusini, Romain, et al.
Publicado: (2023)

Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents
por: Dormont, Flavio, et al.
Publicado: (2020)

Advanced nanomedicines for the treatment of inflammatory diseases
por: Brusini, Romain, et al.
Publicado: (2020)

Formulation and Physicochemical Characterization of Cyclosporine Microfiber by Electrospinning
por: Mirzaeei, Shahla, et al.
Publicado: (2019)

Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation
por: Nakarani, Mahendra, et al.
Publicado: (2010)

Cyclosporine: A Commentary on Brand versus Generic Formulation Exchange
por: Singh, A. K., et al.
Publicado: (2011)

Pharmacokinetics and bioequivalence of two cyclosporine oral solution formulations in cats
por: Yang, Yuxin, et al.
Publicado: (2022)

A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments
por: Periman, Laura M, et al.
Publicado: (2020)

Formulation Strategy for the Delivery of Cyclosporine A: Comparison of Two Polymeric Nanospheres
por: Goyal, Ritu, et al.
Publicado: (2015)

Nanomicelle formulation for topical delivery of cyclosporine A into the cornea: in vitro mechanism and in vivo permeation evaluation
por: Guo, Chuanlong, et al.
Publicado: (2015)

A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca
por: Jerkins, Gary W, et al.
Publicado: (2020)

Chemistry and Structure-Activity Relationship of the Styrylquinoline-Type HIV Integrase Inhibitors
por: Mouscadet, Jean-François, et al.
Publicado: (2010)

Safety, tolerability, and pharmacokinetics of 6-month daily dosing of an oral formulation of cyclosporine (ATOPICA for cats®) in cats
por: Roberts, E S, et al.
Publicado: (2014)

Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies
por: Yu, Yinglan, et al.
Publicado: (2018)

Is Cyclosporine Ototoxic?
por: Waissbluth, Sofia
Publicado: (2020)

Comparison of seven cyclosporine A formulations for dry eye disease: A systematic review and network meta-analysis
por: Gao, Dongyang, et al.
Publicado: (2022)

Cyclosporine: A Review
por: Tedesco, Dustin, et al.
Publicado: (2012)

Cyclosporine-induced Erythromelalgia
por: Bibb, Lorin A, et al.
Publicado: (2018)

Cyclosporine in Cholinergic Itch
por: Sehgal, Sumit, et al.
Publicado: (2022)

Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?
por: Devaux, Christian A., et al.
Publicado: (2021)

Nanomedicine as a strategy to fight thrombotic diseases
por: Varna, Mariana, et al.
Publicado: (2015)

Comparison of Efficacy of Two Different Topical 0.05% Cyclosporine A Formulations in the Treatment of Adenoviral Keratoconjunctivitis-Related Subepithelial Infiltrates
por: Bayraktutar, Betül N., et al.
Publicado: (2016)

A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease
por: Wirta, David L., et al.
Publicado: (2019)

Use of Cyclosporine in Uterine Transplantation
por: Saso, Srdjan, et al.
Publicado: (2012)

Cyclosporin-A associated malignancy
por: Durnian, Jonathan M, et al.
Publicado: (2007)

Cyclosporine and Herbal Supplement Interactions
por: Colombo, D., et al.
Publicado: (2014)

Hyperpigmentation Due to Cyclosporine Therapy
por: Sharma, Ajay N, et al.
Publicado: (2019)

Effect of Fosfomycin on Cyclosporine Nephrotoxicity
por: Ortega-Trejo, Juan Antonio, et al.
Publicado: (2020)

Influence of cyclosporine A on glomerular growth and the effect of mizoribine and losartan on cyclosporine nephrotoxicity in young rats
por: Kim, Ji Hong, et al.
Publicado: (2016)

Could Salivary Cyclosporine Dosage Replace the Whole Blood Cyclosporine Measurements in Renal Transplant Patients?
por: Aboujaoude, Samia, et al.
Publicado: (2017)

Comparative analysis of 0.1% cyclosporin A cationic emulsion and 0.05% cyclosporin A emulsion in murine dry eye cases with different severities
por: Jin, Rujun, et al.
Publicado: (2021)

Cyclosporine Affects the Main Virulence Factors of Cryptococcus neoformans In Vitro
por: de Andrade, Iara Bastos, et al.
Publicado: (2023)

Negative Correlation between Lipid Content and Antibiotic Activity in Streptomyces: General Rule and Exceptions
por: David, Michelle, et al.
Publicado: (2020)

Impact of Phosphate Availability on Membrane Lipid Content of the Model Strains, Streptomyces lividans and Streptomyces coelicolor
por: Lejeune, Clara, et al.
Publicado: (2021)

Well-tolerated oral cyclosporine in a case of hypersensitivity to parenteral cyclosporine in postallogeneic bone marrow transplantation
por: Moeinian, Mahsa, et al.
Publicado: (2018)

Efficacy and Safety of 0.1% Cyclosporine versus 2% Cyclosporine in the Treatment of Severe Vernal Keratoconjunctivitis in Children
por: Bourcier, Tristan, et al.
Publicado: (2022)

Lipid Readjustment in Yarrowia lipolytica Odd-Chain Fatty Acids Producing Strains
por: Abreu, Sonia, et al.
Publicado: (2022)

An efficient system for intracellular delivery of beta-lactam antibiotics to overcome bacterial resistance
por: Abed, Nadia, et al.
Publicado: (2015)

Belatacept: A worthy alternative to cyclosporine?
por: Melvin, George, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_k48bb7lrn3bft1ifraqqs7p1pa